Cargando…

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma

SIMPLE SUMMARY: Uveal Melanoma (UM) is a rare and malignant intraocular tumor with dismal prognosis. Despite efficient control of the primary tumor by radiation or surgery, up to 50% of patients subsequently develop metastases, mainly in the liver. The treatment of UM metastases is challenging and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tarin, Malcy, Némati, Fariba, Decaudin, Didier, Canbezdi, Christine, Marande, Benjamin, Silva, Lisseth, Derrien, Héloïse, Jochemsen, Aart G., Gardrat, Sophie, Piperno-Neumann, Sophie, Rodrigues, Manuel, Mariani, Pascale, Cassoux, Nathalie, Stern, Marc-Henri, Roman-Roman, Sergio, Alsafadi, Samar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136875/ https://www.ncbi.nlm.nih.gov/pubmed/37190207 http://dx.doi.org/10.3390/cancers15082280

Ejemplares similares

Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology
por: Vivet-Noguer, Raquel, et al.
Publicado: (2019)

Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022)

Functional and conformational impact of cancer-associated SF3B1 mutations depends on the position and the charge of amino acid substitution
por: Canbezdi, Christine, et al.
Publicado: (2021)

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
por: Carita, Guillaume, et al.
Publicado: (2016)

Glycolysis Dependency as a Hallmark of SF3B1-Mutated Cells
por: Vivet-Noguer, Raquel, et al.
Publicado: (2022)

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
por: Groenewoud, Arwin, et al.
Publicado: (2023)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
por: Nemati, Fariba, et al.
Publicado: (2023)

Germline MBD4 Mutations and Predisposition to Uveal Melanoma
por: Derrien, Anne-Céline, et al.
Publicado: (2020)

Upcoming translational challenges for uveal melanoma
por: Nabil, Amirouchene-Angelozzi, et al.
Publicado: (2015)

Upcoming translational challenges for uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2015)

Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency
por: Chabot, Thomas, et al.
Publicado: (2022)

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
por: de Koning, Leanne, et al.
Publicado: (2019)

The Prognostic Values of PARP-1 Expression in Uveal Melanoma
por: Gajdzis, Malgorzata, et al.
Publicado: (2021)

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma
por: Mariani, Pascale, et al.
Publicado: (2023)

Prognostic Implications of MRI Melanin Quantification and Cytogenetic Abnormalities in Liver Metastases of Uveal Melanoma
por: Ramtohul, Toulsie, et al.
Publicado: (2021)

Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases
por: Barnhill, Raymond, et al.
Publicado: (2018)

So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020
por: Rodrigues, Manuel, et al.
Publicado: (2019)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

Angiotropism and extravascular migratory metastasis in cutaneous and uveal melanoma progression in a zebrafish model
por: Fornabaio, Giulia, et al.
Publicado: (2018)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
por: Rodrigues, Manuel, et al.
Publicado: (2018)

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies
por: Heijkants, R. C., et al.
Publicado: (2018)

Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020)

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
por: Piperno-Neumann, S., et al.
Publicado: (2023)

Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma
por: Gentien, David, et al.
Publicado: (2023)

Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival
por: Levidou, Georgia, et al.
Publicado: (2021)

EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia
por: Pergaris, Alexandros, et al.
Publicado: (2022)

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
por: Bauer, Sebastian, et al.
Publicado: (2023)

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
por: Park, John J., et al.
Publicado: (2022)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Genetic alterations of SUGP1 mimic mutant-SF3B1 splice pattern in lung adenocarcinoma and other cancers
por: Alsafadi, Samar, et al.
Publicado: (2020)

Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI
por: Mariani, Pascale, et al.
Publicado: (2019)

HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target
por: Souri, Zahra, et al.
Publicado: (2019)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
por: Salaün, Hélène, et al.
Publicado: (2022)

HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma
por: Souri, Zahra, et al.
Publicado: (2020)

Targeting Bcl-2/Bcl-X(L) Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
por: Némati, Fariba, et al.
Publicado: (2014)

Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma
por: Cassoux, Nathalie, et al.
Publicado: (2014)

The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival
por: Dewaele, Shanna, et al.
Publicado: (2021)

Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
por: Glinkina, Kseniya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d6i5a5h7s1kejg5r00fn7f9au4